Drop off your CV/Resume
We'd love to hear from you. Send us your CV/Resume and one of our team will be in touch.
Cellphire Therapeutics: A Company Saving Trauma Patients with Innovative Platelet Therapies
06 Nov, 20254+ minutes
Trauma-related bleeding (hemorrhage) continues to be the primary preventable cause of death for people suffering from a serious injury.
When a hemorrhage occurs, it can spiral out of control quickly. Rapid blood loss prevents oxygen from reaching vital organs and the cardiovascular system begins to collapse; unless the wound is closed and blood loss slowed, death can happen is just a few minutes.
Platelet transfusions are one of the keys to stopping bleeding and helping the body form blood clots. Traditional versions do possess one main drawback, however – and that is an exceedingly short shelf life.
Platelets must be stored at room temperature and are therefore only safe to use for 5-7 days. This poses an array of different problems but mostly means that when there’s a sudden spike in demand (such as a major accident or military conflict), there isn’t enough to go around.
To solve this shelf-life problem, Cellphire Therapuetics are developing an innovative portfolio of platelet transfusions. Their mission involves stopping all deaths from controllable hemorrhages, and so far, they’ve got two promising products that increase shelf life by freezing.
Cellphire Therapeutics
Cellphire is a Maryland-based, clinical-stage biotechnology company on a mission to stop all deaths from controllable hemorrhages. As well as being fully equipped for discovery and research, the organization has a 32,000-square-foot facility where it manufactures all its research products on site.
Their unique technology is being used to revolutionize bleeding treatment and solve the problems caused by traditional platelet therapies. As outlined on their website, their exceedingly short shelf-life results in:
Platelet rationing occurring across the system
Nearly 400,000 platelet units expiring every year before getting to a patient in need
Ten million Americans on anti-platelet or anticoagulant medications facing greater risks when effective therapies aren’t available to clinicians, complicating surgery and trauma care
So far, the company has discovered two groundbreaking platelet products that can be kept on hospital shelves for significantly longer time periods.
Pending platelet therapies
Cellphire’s lead biologic, CLPH-511
CLPH-511 refers to Cellphire’s innovatively frozen, activated platelets – which can be stored for up to 5 years! According to the company’s website, CLPH-511 also has the potential to be more efficacious than traditional platelet therapies and has yet to show any adverse reactions in the several thousands of study subjects.
In March of this year, the FDA granted fast track designation for CLPH-511 for the treatment of acute hemorrhage (as an alternative when conventional platelets aren’t available). This makes CLPH-511 the furthest advanced product in their portfolio.
Freeze-dried Platelet-derived Hemostatic (FPH)
FPH is a first-of-its-kind technology that extends the shelf life of platelets by freeze-drying them.
It is manufactured from FDA licensed, leukocyte reduced, apheresis platelet units taken from volunteers with type O blood. Despite this, it can be infused with patients of any blood type.
Cellphire’s FPH technology has a 3-year shelf life at room temperature and can be stored and deployed with ease. The platelets can be reconstituted with sterile water in a matter of minutes and can be applied to a broad range of medical problems including traumatic brain injury and perioperative bleeding.
Cellphire’s impact
By developing both these groundbreaking platelet therapies, Cellphire has brought us one step closer to better emergency medicine that we so desperately need.
Platelet therapies with extended shelf lives won’t just save hundreds of thousands of traditional platelet units from being wasted – it will ensure people have access to critical treatment when faced with uncontrolled or life-threatening bleeding.
Meet takes pride in helping life sciences organizations build teams that contribute to life-changing medicines and medical devices, just like Cellphire’s innovative platelet therapies.
From clinical stage scale-ups to well established pharma companies, we help place the people that create trial wins and exciting advancements that improve global health outcomes.
If you’re in the biotechnology space and looking to expand an important team or take the next pivotal step in your career, please reach out to us today. Our industry experts will be able to get the process started.
